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Abstract: T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy arising from
T lymphocyte precursors. We have previously shown by miRNA-seq, that miRNAs from the
mir-106a-363 cluster are overexpressed in pediatric T-ALL. In silico analysis indicated their
potential involvement in the regulation of apoptosis. Here, we aimed to test the hypothesis on
the pro-tumorigenic roles of these miRNAs in T-ALL cells in vitro. We demonstrate, for the first
time, that hsa-miR-20b-5p and hsa-miR-363-3p from the mir-106a-363 cluster, when upregulated in
T-ALL cells in vitro, protect leukemic cells from apoptosis, enhance proliferation, and contribute to
growth advantage. We show, using dual luciferase reporter assays, Ago2-RNA immunoprecipitation,
RT-qPCR, and Western blots, that the oncogenic effects of these upregulated miRNAs might, at least
in part, be mediated by the downregulation of two important tumor suppressor genes, PTEN and
BIM, targeted by both miRNAs. Additionally, we demonstrate the cooperative effects of these two
miRNAs by simultaneous inhibition of both miRNAs as compared to the inhibition of single miRNAs.
We postulate that hsa-miR-20b-5p and hsa-miR-363-3p from the mir-106a-363 cluster might serve
as oncomiRs in T-ALL, by contributing to post-transcriptional repression of key tumor suppressors,
PTEN and BIM.
Keywords: oncogenic miRNAs; acute lymphoblastic leukemia; silencing tumor suppressor genes;
miRNA cluster; noncoding RNAs in cancer
1. Introduction
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive, highly heterogeneous type of
lymphoid malignancy, accounting for approximately 15% of pediatric and 25% of adult acute
Cells 2020, 9, 1137; doi:10.3390/cells9051137 www.mdpi.com/journal/cells
Cells 2020, 9, 1137 2 of 19
lymphoblastic leukemia (ALL) cases. T-ALL arises from T-cell precursors (thymocytes) during
their maturation in the thymus upon accumulation of numerous genetic lesions and cooperating
aberrations affecting epigenetic and post-transcriptional regulation of gene expression [1–6]. Thus,
T-ALL is characterized by a multiplicity of chromosomal rearrangements, copy number alterations,
and sequence mutations, leading to activation of oncogenes and inactivation of tumor suppressor genes,
which ultimately result in altered gene expression profiles, as a consequence of triggering of oncogenic
pathways and transcriptional programs [5,6]. These collectively lead to the dysfunction of key processes
involved in the maturation of thymocytes and cause a block of differentiation, the impairment of
apoptosis and cell cycle, as well as excessive proliferation. Among the genetic aberrations observed in
T-ALL, there are lesions occurring commonly in many other cancers (e.g., inactivating mutations and
deletions of PTEN and TP53 genes, activating gene mutations of the JAK-STAT pathway) as well as
T-ALL-specific lesions, mainly affecting transcription factors crucial for normal differentiation of T-cell
precursors (e.g., BCL11B, TAL1, TAL2, LYL1).
With such a complex molecular background, T-ALL presents as a highly heterogeneous malignancy.
This heterogeneity is observed at the immunophenotypic, genetic and potentially also at the epigenetic
level. Better understanding of the biology of this disease, the identification of novel components
of oncogenic pathways and potentially druggable targets are needed for further improvements in
T-ALL treatment strategies. The recent effort is to exploit the possibilities offered by next generation
sequencing (NGS) technologies, including those extending beyond the coding part of the genome,
to further unravel the complexity of the (epi)genomic and transcriptomic background of T-ALL [7–12]
and to understand the functional consequences of these aberrations.
miRNAs constitute a class of non-coding RNAs, extensively studied for their contribution to
tumorigenesis by their involvement in the regulation of key cellular functions such as cell proliferation,
apoptosis, migration, and many others. miRNAs are involved in the negative regulation of gene
expression at post-transcriptional level in health and disease. When aberrantly expressed, miRNAs
may act as oncogenes or as suppressors of neoplastic transformation, by silencing the expression
of tumor suppressor mRNAs or by insufficient silencing of oncogenic mRNAs, respectively [2].
The biological role of miRNAs lies in their involvement in intricate networks of regulatory interactions:
miRNA-mRNA interactions, but also co-operative actions of many miRNAs and interactions with
other non-coding RNAs [2,13,14].
miRNA-mediated regulation of gene expression is a complex phenomenon. Single miRNA may
target multiple mRNAs, and single mRNA may contain MRE (miRNA responsive element) sequences
for many miRNAs. miRNAs often act as ‘functional groups’ co-regulating the same cellular processes,
e.g., clusters of miRNAs transcribed as polycistronic primary transcript or structurally unrelated but
co-expressed and functionally related miRNAs. Such clustered and co-expressed miRNAs collectively
contribute to phenotypic effects. Thus, the oncogenic or tumor suppressor potential of particular miRNA
is rarely the effect of targeting single mRNA, but is more the ‘net-effect’ of the regulation of multiple
targets by several co-operating miRNAs [2]. This also implies that the biological effects of a single
miRNA on the expression of a single target gene are usually mild. Thus, the “fine-tuning” regulatory
effects of miRNAs over mRNA transcriptome should be studied in a broad context. Next generation
sequencing enabling the global investigation of miRNA expression, followed by extensive in silico
analysis of related mRNAs and biological processes, is currently an optimal option to select candidate
miRNAs for functional analyses.
The miRNA transcriptome in pediatric T-ALL has been recently comprehensively characterized
by NGS [11] also by our group [12]. We identified a set of differentially expressed miRNAs in primary
pediatric T-ALL cases as compared to normal mature T-cells. Among miRNAs overexpressed in T-ALL,
we found four miRNAs (hsa-miR-20b-5p, miR-20b-3p, miR-18b-5p and hsa-miR-363-3p) that belong to
the mir-106a-363 cluster. This miRNA cluster is a paralog of mir-17-92, a prototypic oncogenic cluster of
an eminent role in many types of cancer, including T-ALL [15]. Interestingly, miRNAs from mir-17-92
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cluster were not overexpressed in our T-ALL cohort. The role of miRNAs from the mir-106a-363 cluster
has not been extensively studied in the context of T-ALL.
In the present study, we aimed to test the hypothesis on the oncogenic roles of hsa-miR-20b-5p
and hsa-miR-363-3p, both from mir-106a-363 cluster, in T-ALL cells in vitro.
We demonstrate that hsa-miR-20b-5p and hsa-miR-363-3p affect the expression of two important
tumor suppressor genes, PTEN and BIM. We also show that mimicry and inhibition of these
miRNAs have impact on the survival of T-ALL cells in vitro, by affecting spontaneous apoptosis and
proliferation. Thus, we postulate that hsa-miR-20b-5p and hsa-miR-363-3p, might act as oncomiRs
when overexpressed in T-ALL and we indicate PTEN and BIM as potential important mediators of
these effects.
2. Materials and Methods
2.1. miRNA Selection and Target Prediction
The selection of miRNAs analyzed in the present study (hsa-miR-20b-5p, hsa-miR-363-3p) was
based on their overexpression in primary T-ALL samples (34 pediatric T-ALL cases and an independent
cohort of 32 pediatric T-ALL cases in the validation cohort) as compared to normal mature T-cells,
CD34+, and CD4+CD8+ normal thymocytes, as described previously [12,16].
Target genes analyzed in the present study were selected based on target prediction and pathway
enrichment analysis, performed for miRNAs differentially expressed between T-ALL samples and
controls in the miRNA-seq study [12]. Briefly, 8 target prediction algorithms, 3 databases of validated
miRNA-mRNA interactions and 3 databases of miRNA-mRNA interactions related to diseases and
drug response were used. Genes predicted as targets for differentially expressed miRNAs by more
than 5 algorithms were then analyzed for enrichment in Gene Ontology (GO) and Kyoto Encyclopedia
of Genes and Genomes (KEGG) terms and pathways. For the details of the target prediction and
overrepresentation analysis, refer to our previous work [12].
2.2. Primary T-ALL Samples and Control Samples
T-ALL cells were isolated by immunomagnetic selection from bone marrow mononuclear cells
obtained at primary diagnosis, as previously described [12]. Bone marrow samples were collected
from T-ALL patients and from 5 healthy unrelated bone marrow donors aged <18 years with the
informed consent of the patients/legal guards, in accordance with Declaration of Helsinki. Samples were
collected at the centers of Polish Pediatric Leukemia and Lymphoma Study Group. The study was
approved by the Ethics Committee of the Medical University of Silesia (KNW/0022/KB1/145/I/11/12
and KNW/0022/KB1/153/I/16/17).
Thymocyte samples, obtained as previously described [11,17] were used as controls. RNA isolated
from thymocytes (3 CD34+ and 3 CD4+CD8+) was used in RT-qPCR expression analysis of the studied
miRNAs in T-ALL primary samples and 6 T-ALL cell lines, to extend the previous validation [12,16]
(Figure 1). Human thymus samples were used following the guidelines of, and were approved by,
the Ethical Committee of the Ghent University Hospital (Belgium).
2.3. Cell Lines
The HEK293T cell line was a kind gift from Prof. Maciej Kurpisz lab (Institute of Human Genetics,
Polish Academy of Sciences, Poland). Cells were cultured under standard conditions in Dulbecco’s
modified Eagle’s medium (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) with 10% fetal bovine
serum (Gibco, Thermo Fisher Scientific) and 1% penicillin/streptomycin solution (Sigma Aldrich,
St. Louis, MO, USA). Six T-ALL cell lines: DND-41, CCRF-CEM, Jurkat, BE-13, P12-Ichikawa and
MOLT-4, were purchased from the Leibniz Institute DSMZ—German Collection of Microorganisms and
Cell Cultures. Cells were cultured under standard conditions in RPMI-1641 medium (Gibco, Thermo
Fisher Scientific) with 10% fetal bovine serum (Gibco, Thermo Fisher Scientific).
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Figure 1. Expression of hsa-miR-20b-5p (A) and hsa-miR-363-3p (B) evaluated by RT-qPCR in T-cell 
acute lymphoblastic leukemia (T-ALL) patients, normal T-cells from bone marrow (BM T-cells), 
CD34+ thymocytes, CD4+ CD8+ thymocytes and T-ALL cell lines. *** p < 0.001; * p < 0.05; ns—not 
significant. 
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Figure 1. Expression of hsa-miR-20b-5p (A) and hsa-miR-363-3p (B) evaluated by RT-qPCR in T-cell
acute lymphoblastic leukemia (T-ALL) patients, normal T-cells from bone marrow (BM T-cells), CD34+
thymocytes, CD4+ CD8+ thymocytes and T-ALL cell lines. *** p < 0.001; * p < 0.05; ns—not significant.
2.4. RNA Extraction and RT-qPCR
The miRCURY RNA Isolation Kit Cell & Plant (Qiagen, Hilden, Germany) was used for the
extraction of total RNA including the recovery of the small RNA fraction. RNA isolates were
DNase treated and purified with use of RNA Clean and Concentrator Kit (Zymo Research, Irvine,
CA, USA). RNA concentration was measured with Quantus Fluorometer (Promega, Madison,
WI, USA) using Qubit HS RNA Assay Kit (Thermo Fisher Scientific). RNA integrity was determined
with 4200 Tapestation using High Sensitivity RNA ScreenTape (Agilent Technologies, Santa Clara,
CA, USA) and 2100 Bioanalyzer using RNA 6000 Nano Assay (Agilent Technologies). For miRNA
quantification, total RNA was reverse transcribed with TaqMan Advanced miRNA cDNA Synthesis
Kit (Thermo Fisher Scientific) according to the manufacturer’s protocol. TaqMan Fast Advanced
Master Mix and predesigned TaqMan Advanced miRNA assays (Thermo Fisher Scientific) were used.
Three endogenous control miRNAs (hsa-miR-16-5p, hsa-let-7a-5p and hsa-miR-25-3p) were selected
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using a strategy based on a comprehensive assessment of expression stability in our miRNA-seq data
and in RT-qPCR, as previously described [16]. For mRNA quantification, total RNA was reverse
transcribed with iScript cDNA Synthesis Kit (Bio Rad, Hercules, CA, USA) and HOT FIREPol EvaGreen
qPCR Mix Plus (Solis Biodyne, Tartu, Estonia) was used. Primers were synthetized by Genomed
(Warsaw, Poland). List of primers used for mRNA quantification is presented in Supplementary
Table S1. Geometric mean of B-actin and GAPDH expression was used for normalization of expression
of the analyzed target genes. All RT-qPCR analyses were conducted in three technical and three
biological replicates (three independent, time-separated transfections) with the use of 7900HT Fast
Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). Comparative deltaCT method
(∆∆CT) and Data Assist Software v. 3.01 (Thermo Fisher Scientific) were used for relative quantification
of expression [18].
2.5. Dual Luciferase Reporter Assay
Selected predicted miRNA-mRNA interactions were validated with Dual-Glo Luciferase Reporter
Assay (Promega, Madison, WI, USA). HEK 293T cells were seeded on 24-well culture plate 24 h
before transfection. Cells were subjected to transfection at 60% to 80% confluency using JetPrime
DNA/siRNA Transfection Kit (Polyplus Transfection, New York, NY, USA) to enable co-transfection
with relevant miRNA mimics or negative control mimics (MirVana, Thermo Fisher Scientific) and
pmirGLO plasmids (Promega), containing 3′UTR fragments of the selected target genes. miRNA mimics
in final concentration of 50 µM and 125 ng of plasmid were used per well. 3′UTR fragments cloned
into pmirGLO plasmid contained the predicted 6-8 nt long miRNA response element (MRE), flanked
with 30 nt long regions on both sides. In Dual Luciferase rescue experiments, 4 point mutations were
introduced to the MRE region during the oligonucleotide synthesis step to abolish the miRNA-mRNA
interaction. The list of oligonucleotides containing wild type/mutated MRE sequences with flanking
sites is presented in Supplementary Table S2. Luciferase activity was measured with GloMax-Multi+
Detection System (Promega) after 48 h from transfection. All experiments were performed in three
replicates. A significant decrease in luciferase activity relative to control (negative control miRNA) was
indicative of direct interaction between the seed sequence of the miRNA (defined as the nucleotides at
position 2–7 of the 5’ end of mature miRNA sequences) and the MRE in the 3′UTR of target mRNA.
2.6. Transfection of T-ALL Cell Lines
T-ALL cell lines were transfected with negative control, hsa-miR-20b-5p and hsa-miR-363-3p
mimics and inhibitors (miRVana, Thermo Fisher Scientific). Mimics and inhibitors were used in the
final concentration of 50 nM and 100 nM, respectively. Cells were electroporated with the use of the
Neon Electroporation System according to the manufacturer’s protocol. Briefly, cells were resuspended
in Neon Resuspension R Buffer (Thermo Fisher Scientific) at a concentration of 20 × 106 cells/mL and
transferred to Neon Tips. Electroporation was conducted under following conditions: for DND-41
pulse voltage 1150 V, pulse width 30 ms, pulse number 2; for CCRF-CEM pulse voltage 1600 V,
pulse width 20 ms, pulse number 1.
2.7. Western Blotting
After transfection, 3 × 106 cells per well were seeded on 6-well plate in 2 mL of culture medium.
After 24, 48, and 72 h, half of the cells from each well was collected and lysed in 200 µL of RIPA
buffer with protease inhibitor cocktail and EDTA (Thermo Fisher Scientific). Protein concentration was
determined using Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). Proteins were separated
on 4%–15% Mini-PROTEAN TGX Stain-free Gel (Bio Rad). After electrophoresis, proteins were
transferred onto 0.45 µm PVDF Low Fluorescence membrane (Bio Rad). Membranes were blocked
using 5% non-fat milk or BSA and incubated with 1:2000 anti-PTEN (Cell Signaling Technology,
#9552), 1:2000 anti-BIM (Cell Signaling Technology, Danvers, MA, USA, #2933), 1:750 anti-FBXW7
(Abcam, Cambridge, UK, AB109617) or 1:2000 anti-SOS1 (Cell Signaling Technology, #12409) antibodies.
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After washing, membranes were incubated with horseradish peroxidase (HRP) conjugated with
1:40,000 (for PTEN, BIM and SOS1) or 1:20,000 (for FBXW7) anti-Rabbit (Abcam, ab97051) secondary
antibody. Immunoreactive protein bands were detected with Clarity Western ECL Substrate for HRP
(Bio-Rad) on Chemidoc Imaging System (Bio Rad). The abundance of target protein was assessed in
reference to the total protein on a blot in Stain-Free technology using Image Lab 6.0.1 software (Bio Rad).
Each experiment was conducted in three technical and three biological replicates (three independent,
time-separated transfections). Whole total protein membranes and chemiluminescence blots are shown
in Supplementary Figure S1.
2.8. AGO2-RNA Immunoprecipitation and RT-qPCR
For each immunoprecipitation reaction 3 × 107 DND-41 cells were collected and crosslinked with
1% formaldehyde in PBS for 10 min in room temperature. The crosslinking was stopped by adding
glycine to the final concentration of 0.25 M. Immunoprecipitation was performed with the use of Magna
RIP Kit (Merck, Darmstadt, Germany). Each portion of Protein A/G magnetic beads was coated with 5µg
of either anti-Ago2 (Abnova, Taipei, Taiwan, H00027161-M01) or normal mouse IgG (Merck, CS200621)
antibody. Non-RNA binding normal mouse IgG was used as negative control. Lysates from crosslinked
cells were prepared according to the manufacturer’s protocol and incubated with antibody-conjugated
magnetic beads in 4 ◦C with rotation overnight. After incubation, magnetic beads were washed and
treated with proteinase K to release the RNA from ribonucleoprotein complexes. RNA was purified
through Trizol isolation combined with Zymo RNA Clean and Concentrator columns. Equal volumes
of immunoprecipitated mRNA and miRNA fractions from Ago2-RIP and IgG-RIP samples were
reverse transcribed as described above. The abundance of hsa-miR-20b-5p, hsa-miR-363-3p, PTEN and
BIM in the AGO2-RIP and IgG-RIP fraction was assessed by RT-qPCR. Fold enrichment of examined
miRNAs and target mRNAs in AGO2-RIP fraction was calculated as 2-∆Cq (Cq—quantification cycle),
where ∆Cq = Cq(AGO2-RIP) − Cq(IgG-RIP).
2.9. Cell Viability Assay
After transfection, 2 × 104 cells per well were seeded on 96-well plate in 100 µL of culture medium.
After 0, 24, 48, 72, and 96 h, 10 µL of Cell Counting Kit 8 (Sigma Aldrich) reagent was added to each
well. Cells were incubated with CCK8 reagent for 4 h in 37 ◦C. Absorbance was measured on the
GloMax-Multi+ Detection System (Promega). Each experiment was conducted in five technical and
three biological replicates (three independent, time-separated transfections).
2.10. Apoptosis Assay
After transfection, 1.5 × 106 cells per well were seeded on 12-well plate in 1 mL of culture
medium. After 24, 48, and 72 h, half of the cells from each well were collected and stained with
Annexin V PE 7-AAD Apoptosis Detection Kit (BD Biosciences, San Jose, CA, USA). Populations
of apoptotic and non-apoptotic cells were detected with a FlowSight flow cytometer (Luminex
Corporation, Austin, TX, USA). Results were analyzed in Ideas 6.2 Software (Luminex Corporation).
Each experiment was conducted in three biological replicates (three independent, time-separated
transfections). Representative apoptosis plots are shown in Supplementary Figure S2.
2.11. Cell Cycle Assay
After transfection 1.5 × 106 cells per well were seeded on 12-well plate in 1 mL of culture medium.
After 24, 48, and 72 h, half of the cells from each well was collected and fixed with methanol. Cells were
then stained with propidium iodide (Sigma Aldrich). Populations of cells in G0/G1, S and G2/M phase
were detected with the use of S3e Cell Sorter (Bio Rad). Results were analyzed in ModFit Software
(Verity Software House, Topsham, ME, USA). Each experiment was conducted in three biological
replicates (three independent, time-separated transfections).
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2.12. Statistical Analysis
For the comparison of two independent means, data were analyzed for normality with
Shapiro–Wilk test and next the two groups were tested for equality of variances. Statistical significance
of the results was calculated with unpaired two-tailed t-test or nonparametric Mann–Whitney test.
For proliferation assays, statistical significance was calculated with a mixed model analysis using
the Tukey post-hoc test. All analyses and data visualization were performed with GraphPad Prism
8 software.
3. Results
3.1. hsa-miR-20b-5p and hsa-miR-363-3p are Overexpressed in T-ALL and Target Genes Involved in Regulation
of Apoptosis
Following our previous miRNA-seq study in pediatric T-ALL primary samples, including
validation of miRNA expression by RT-qPCR in the discovery and validation cohort [12,16], we here
performed additional RT-qPCR in 6 T-ALL cell lines (DND-41, CCRF-CEM, JURKAT, MOLT-4,
P12-ICHIKAWA, and BE-13) to select an optimal model for in vitro experiments. We used 3 types of
control cells: Normal mature T lymphocytes, CD34+ thymocyte samples, and CD4+CD8+ thymocyte
samples. hsa-miR-20b-5p exhibited high level of expression in all examined T-ALL cell lines as
compared to all types of control cells (Figure 1A). The expression of hsa-miR-363-3p was higher in
DND-41, JURKAT, and P12-ICHIKAWA cell lines than in normal CD34+ T-cells. Yet, only DND-41
showed higher hsa-miR-363-3p expression level as compared to CD34+ and CD4+CD8+ thymocytes
(Figure 1B). We confirmed overexpression of hsa-miR-20b-5p and hsa-miR-363-3p in a total cohort
of T-ALL patients as compared to normal T-cells and in case of hsa-miR-20b-5p also as compared to
CD4+CD8+ thymocytes (Figure 1). Of note, despite the overall overexpression of these miRNAs in
T-ALL patients’ group, the expression levels were varying, which is in agreement with the considerable
heterogeneity of this disease. For in vitro experiments aimed at the assessment of the phenotypic
effects of hsa-miR-20b-5p and hsa-miR-363-3p mimicry and inhibition, we selected easy to transfect cell
lines with varying endogenous levels of the studied miRNAs: DND-41 with high levels of both studied
miRNAs and CCRF-CEM with high level of miR-20b-5p and low level of miR-363-3p, comparable to
the expression levels in a subset of T-ALL patients.
To establish the potential molecular consequences of the upregulation of the two miRNAs from
cluster miR-106a-363, we used data from our bioinformatic target gene prediction and pathway
enrichment analysis [12]. Genes predicted as targets for differentially expressed miRNAs by at least
5 algorithms and analyzed for enrichment in Gene Ontology (GO) and Kyoto Encyclopedia of Genes
and Genomes (KEGG) terms and pathways indicated several processes of potential importance for
T-ALL pathogenesis. Notably, one of the top 10 highly enriched GO terms was “Positive regulation
of apoptosis” (GO:0043065). Interestingly, many target genes enriched in this term were predicted
to be targeted, and thus silenced, by hsa-miR-20b-5p and hsa-miR-363-3p (Supplementary Table S3).
We performed luciferase reporter assays in human embryo kidney HEK293T cell line to validate several
selected interactions of hsa-miR-20b-5p and hsa-miR-363-3p with their predicted targets, as described
in details in Supplementary Materials. We confirmed the majority of the predicted interactions; most of
them have not been annotated in databases of validated interactions thus far.
3.2. hsa-miR-20b-5p and hsa-miR-363-3p Downregulate PTEN and BIM in T-ALL Cells In Vitro
We further aimed to test if these two miRNAs affect the expression of selected target genes
enriched in the ‘Positive regulation of apoptotic process’ GO term. Using RT-qPCR and Western
blotting, we assessed the changes in the expression of target genes after inhibition and mimicry of
studied miRNAs. We focused on the interactions of hsa-miR-20b-5p and hsa-miR-363-3p with PTEN
and BIM. Of note, both these genes are validated targets of both studied miRNAs, which might
potentially reveal the cooperative effects of the “clustered” miRNAs on the cells’ phenotype.
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The interaction of hsa-miR-20b-5p-PTEN has previously been demonstrated (Supplementary
Table S4) and also confirmed by us in luciferase reporter assays (Supplementary Figure S3A) [12].
hsa-miR-363-3p-PTEN interaction, which we validated by luciferase assay (Supplementary Figure S3B) [12],
has not been previously reported by others. hsa-miR-20b-5p-BIM and hsa-miR-363-3p-BIM were not
covered by our overrepresentation analysis (both were predicted by 4 and not by 5 algorithms),
but have previously been reported by different approaches (Supplementary Table S4). We included
these interactions in further experiments for the clear involvement of BIM (encoding a pro-apoptotic
protein) in the positive regulation of apoptosis. Additionally, we selected for RT-qPCR and Western
blotting experiments the interactions of the less evident role in apoptosis: hsa-miR-20b-SOS1 and
hsa-miR-363-FBXW7. For miRNA mimicry and inhibition we have used the DND-41 cell line, as the
most optimal model, since it is negative for PTEN and FBXW7 inactivating mutations or deletions [19]
and it exhibits high endogenous expression of both studied miRNAs (Figure 1). Additionally, we used
CCRF-CEM cell line, showing relatively high expression of hsa-miR-20b-5p but low expression of
hsa-miR-363-3p, comparable to that in normal T-cells, but also in a subset of T-ALL patients (Figure 1).
CCRF-CEM cell line is characterized by lack of PTEN expression due to deletion and mutation in this
gene [19,20].
We demonstrated that inhibition of hsa-miR-20b-5p and hsa-miR-363-3p in DND-41 cells
(showing high endogenous levels of both miRNAs) resulted in statistically significant increase
of PTEN mRNA expression (p = 0.028 for hsa-miR-20b-5p and p = 0.004 for hsa-miR-363-3p) and
increase of PTEN protein level (p = 0.025 for hsa-miR-20b-5p and p = 0.0011 for hsa-miR-363-3p)
(Figure 2A). We did not observe the effects of the overexpression of these miRNAs (by miRNA mimics)
on PTEN expression, potentially due to the already high endogenous levels of these miRNAs.
The inhibition of hsa-miR-20b-5p in DND-41 cell line resulted in an increase of BIM mRNA
(p = 0.043) and BIM protein (p = 0.029) expression. This effect was also observed for the hsa-miR-363-3p
inhibitor, with statistical significance only at the protein level (p = 0.009) (Figure 2B). Moreover, mimicry
of hsa-miR-363-3p resulted in decrease of BIM mRNA expression (p = 0.011) and BIM protein (p = 0.002)
(Figure 2B). While the mimicry of hsa-miR-20b-5p resulted in decrease of BIM only at the protein level
(p = 0.024) (Figure 2B).
In CCRF-CEM cell line we observed statistically significant effects of the hsa-miR-20b-5p inhibition
on the increase of BIM protein level (p = 0.03). We did not observe the effects of hsa-miR-20b-5p
mimicry, potentially due to the high endogenous level of this miRNA in this cell line. As expected,
for the hsa-miR-363-3p (with low endogenous level in these cells) we only observed the effects of the
overexpression of this miRNA on BIM expression (both at the mRNA, p = 0.045; and protein level,
p = 0.019); we did not observe the effects of hsa-miR-363-3p inhibition.
As for the miRNA interactions with the other two genes (SOS1 and FBXW7) also enriched in
“Positive regulation of apoptotic process” GO term, but with less obvious functional link to this process,
the effects of miRNA inhibition and mimicry were less convincing. In DND-41 cells, the mimicry of
hsa-miR-20b-5p resulted in statistically significant decrease of SOS1 mRNA (p = 0.035) and protein
(p = 0.03) level; inhibition resulted in increase of protein expression (p = 0.042) (Supplementary
Figure S4A) Yet, such effects were not observed in CCRF-CEM cells (Supplementary Figure S4B).
In case of FBXW7, mimicry of hsa-miR-363-3p resulted in decreased mRNA level in DND-41 cell,
yet these changes were not statistically significant (a trend was observed; p = 0.059) and were not
reflected at protein level. We did not observe any significant effects of miRNA mimicry and inhibition
in the CCRF-CEM cell line (Supplementary Figure S4C,D). For these reasons, we excluded these
miRNA-mRNA interactions from further experiments.
Thus, by a combined use of miRNA mimics and inhibitors, we demonstrated that hsa-miR-20b-5p
and hsa-miR-363-3p both, to various extend, regulate the expression of PTEN and BIM tumor
suppressor genes in T-ALL cells in vitro. To provide additional evidence for these two miRNAs exerting
posttranscriptional silencing of PTEN and BIM in T-ALL cells, we performed RNA immunoprecipitation
(RIP) in non-transfected DND-41 cells with the use of an antibody against AGO2. AGO2 is the
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component of RNA-induced silencing complex (RISC). AGO2-RIP followed by RT-qPCR analysis of
immunoprecipitated RNA enabled to demonstrate the enrichment of hsa-miR-20b-5p, hsa-miR-363-3p,
PTEN and BIM in AGO2-RIP fraction as compared to control IgG-RIP fraction (immunoprecipitation
with use of normal mouse IgG) (Supplementary Figure S5). Thereby, we showed that both these
miRNAs and both their target mRNAs interact in RISC complexes in T-ALL cells.Cells 2020, 9, x FOR PEER REVIEW 9 of 20 
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3.3. hsa-miR-20b-5p and sa- iR-363-3 Exert Anti-Apoptotic and Pro-Proliferative Effects in T-ALL Cells
In Vitro
Finally, we assessed the phenotypic effects of the downregulation and upregulation of
hsa-miR-20b-5p and hsa-miR-363-3p on the apoptosis, viability and cell cycle of DND-41 and
CCRF-CEM cell lines. We transfected T-ALL cells with the mimics and inhibitors of the studied
miRNAs and performed flow cytometry analysis of apoptosis. Inhibition of hsa-miR-20b-5p and
hsa-miR-363-3p in DND-41 cells resulted in increased number of apoptotic cells in comparison to
negative control (p = 0.0065 for hsa-miR-20b-5p and p = 0.025 for hsa-miR-363-3p) indicating stimulation
of spontaneous apoptosis of the cells upon downregulation of these miRNAs (Figure 3A). Of note,
the mimicry of these miRNAs resulted in no significant changes in e number of apoptotic DND-41
cells, which was in line ith the results of mRNA and protein expression analysis—statistically
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significant effects were mainly observed for the inhibitors, and less for the mimics (Figure 2A,B).
In CCRF-CEM cell line the inhibition of hsa-miR-20b-5p resulted in enhanced apoptosis of the cells
p = 0.038), while overexpression of hsa-miR-20b-5p and also of hsa-miR-363-3p, by the use of miRNA
mimics, caused reduction in the number of apoptotic cells as compared to controls (p = 0.006 for
hsa-miR-20b-5p and p = 0.017 for hsa-miR-363-3p) (Figure 3A). These confirmed our observation
from the DND-41 cell line on the enhanced apoptosis upon downregulation of these miRNAs and
additionally demonstrated resistance to spontaneous apoptosis upon upregulation of these miRNAs.
These results also largely reflect the pattern of the effects of miRNA inhibition and mimicry in mRNA
and protein expression analysis (Figure 2C). This data implies that upregulated levels of hsa-miR-20b-5p
and hsa-miR-363-3p in T-ALL cells protect them from apoptosis and thus might promote their survival.
In the next step, we evaluated the effects of miRNA mimicry and inhibition on the survival of
T-ALL cells in vitro. In both cell lines, we observed statistically significant increase in the viability of
T-ALL cells after overexpression of hsa-miR-20b-5p (p < 0.0001 for DND-41 and also for CCRF-CEM)
and reduction of viability after hsa-miR-20b-5p inhibition (p < 0.0001 for both cell lines) (Figure 3B).
Introduction of hsa-miR-363-3p mimics to DND-41 cells had moderate effect (p = 0.0121), but inhibition
of this miRNA resulted in significant reduction of viability (p < 0.0001). Moreover, we observed
enhanced viability of CCRF-CEM cells upon overexpression of hsa-miR-363-3p (p = 0.0036). We did
not observe statistically significant effects of hsa-miR-363-3p inhibition in CCRF-CEM cells (Figure 3B),
potentially due to low endogenous level of this miRNA in these cells. This observation was in line with
no effects of hsa-miR-363-3p inhibition on mRNA nor protein level of BIM in these cells (Figure 2C).
For these reasons, we did not test this variant (hsa-miR-363-3p inhibition) in further experiments in
this cell line.
Interestingly, despite increased survival of DND-41 cells upon mimicry of hsa-miR-20b-5p and
hsa-miR-363-3p (Figure 3B), we observed no differences in the apoptosis of these cells (Figure 3A).
Thus, we hypothesized that the higher viability of DND-41 cells upon miRNA mimicry is caused by
enhanced proliferation rather than suppressed apoptosis. To test this, we performed flow cytometry
assay for cell cycle distribution to assess the percentage of non-dividing and dividing cells. In DND-41
cells, mimicry of hsa-miR-20b-5p and hsa-miR-363-3p resulted in decreased number of the cells in
G0/G1 phase (p = 0.006 for hsa-miR-20b-5p and p = 0.048 for hsa-miR-363-3p) and increased number of
cells in G2/M (p = 0.014 for hsa-miR-20b-5p and p = 0.036 for hsa-miR-363-3p) and S phase (p = 0.0022
for hsa-miR-20b-5p) (Figure 3C), thus confirming our assumption on the enhanced proliferation rate of
T-ALL cells upon overexpression of these miRNAs. In CCRF-CEM cells, the effects were less profound,
overexpression of hsa-miR-20b-5p resulted in an increased number of proliferating cells (p = 0.032
for cells in G2/M phase as compared to negative control), while inhibition of this miRNA gave the
opposite effect (p = 0.0092) (Figure 3C). We observed no statistically significant differences in cell cycle
distribution in CCFR-CEM cell line upon overexpression of hsa-miR-363-3p.
We further hypothesized that the functional effects mediated by the cooperative action of these two
miRNAs are greater than the effect of a single miRNA. We performed another set of apoptosis, growth
and cell cycle assays to compare the effects of the simultaneous inhibition of both clustered miRNAs
versus inhibition of single miRNAs. To this aim we chose DND-41 cell line, since both studied miRNAs
are highly expressed in these cells (Figure 1) and both, PTEN and BIM are expressed (Figure 2A,B).
Indeed, the concurrent inhibition of both miRNAs resulted in higher percentage of apoptotic cells in
DND-41 culture than in culture variants with single miRNA inhibitors (p = 0.0014 for simultaneous
inhibition vs. hsa-miR-363-3p inhibition; p = 0.07 for simultaneous inhibition vs. hsa-miR-20b-5p
inhibition) (Figure 4A). This observation was in line with the decreased growth of cells transfected by
both inhibitors as compared to negative control (p < 0.0001) and as compared to cells transfected with
single inhibitors (p = 0.0143 for hsa-miR-363-3p inhibition; p = 0.0234 for hsa-miR-20b-5p inhibition)
(Figure 4B). As earlier, we observed no clear differences in cell cycle distribution after inhibition of
single miRNAs (Figure 3C) but simultaneous inhibition of both miRNAs resulted in slight increase of
percentage of cells in G0/G1 phase as compared to the control (p = 0.043) (Supplementary Figure S6).
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4. Discussion
Here we aimed to investigate if hsa-miR-20b-5p and hsa-miR-363-3p act as oncogenic miRNAs
in T-ALL cells in vitro. We selected these miRNAs since they belong to one cluster of miRNAs
(mir-106a-363), showed overexpression in a substantial number of primary T-ALL samples in our
previous miRNA-seq study and both potentially silence genes involved in positive regulation
of apoptosis (Supplementary Table S3) [12]. Some of these genes, like PTEN, FBXW7, or BIM,
have already established tumor suppressive and pro-apoptotic roles [6,21–23], yet their interactions
with hsa-miR-20b-5p and hsa-miR-363-3p have not been studied functionally in T-ALL thus far.
We aimed to test, if silencing of these genes by upregulated hsa-miR-20b-5p and hsa-miR-363-3p may
contribute to oncogenic mechanism in T-ALL cells in vitro.
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PTEN is a negative regulator of PI3K/AKT pathway and thus is involved in the inhibition of cell
growth and proliferation and in the promotion of apoptosis [22]. PTEN is affected by deletions and/or
inactivating mutations in many types of malignancies, including T-ALL, contributing to oncogenic
activation of PI3K-AKT pathway [20,22,24,25]. In pediatric T-ALL, PTEN abnormalities are found
in approx. 15% of pediatric T-ALL cases and have been shown, also by our group, to be related to
therapy resistance and poor prognosis [26–29]. BIM (alias BCL2L11) encodes a protein from BCL-2
family of apoptosis-related proteins acting as apoptotic activator [21]. BIM has been demonstrated to
be repressed by upregulated MYC and PI3K-AKT pathways resulting in enhanced survival of T-ALL
cells [30]. Mutations of BIM have been shown to induce resistance to apoptosis despite downregulation
of MYC in T-ALL zebrafish model [31]. FBXW7 is involved in ubiquitination and degradation of MYC
and NOTCH1 [32]. While MYC is a “pan-cancer” oncogene [33], NOTCH1 is more “T-ALL-specific”.
It acts as a ligand-activated transcription factor, critical for the differentiation and development of
early T-cell precursors in the thymus [34]. Inactivating mutations of FBXW7 (identified in approx. 30%
of T-ALL cases and frequently co-occurring with activating NOTCH1 mutations) result in decreased
degradation of activated NOTCH1 [5]. We additionally investigated SOS1 gene, which role in T-ALL
is much less understood. SOS1 is involved in the activation of RAS pathway [35,36], thus it is more
likely to be involved in the negative, and not positive, regulation of apoptosis. SOS1 was also shown
to be crucial for early T-cell development; its knockout in mice resulted in differentiation blockade of
thymocytes [37].
To test if hsa-miR-20b-5p and hsa-miR-363-3p cause silencing of PTEN, BIM, FBXW7, and SOS1,
we applied miRNA mimicry and inhibition in T-ALL cells in vitro. We selected two easy to transfect
T-ALL cell lines with varying endogenous levels of the studied miRNAs: DND-41 with high levels of
both studied miRNAs and CCRF-CEM with high level of miR-20b-5p and low level of miR-363-3p.
The choice was aimed to reflect the heterogeneity of the disease, observed also at the miRNA
transcriptome level [12].
Since in humans and animals, the mechanism of miRNA-mediated regulation of gene expression
relies more on blocking of translation rather than mRNA degradation, we assessed mRNA and protein
expression. We demonstrated regulatory effects of hsa-miR-20b-5p and hsa-miR-363-3p over BIM
(in both T-ALL cell lines) and PTEN (in DND-41 cells). Targeting of BIM and PTEN by hsa-miR-20b-5p
and hsa-miR-363-3p was reflected by decreased levels of proteins upon miRNA mimicry and by the
reverse effects upon miRNA inhibition; in some cases the effects were also seen at the mRNA level
(Figure 2). Of note, these regulatory effects were not observed in every variant of miRNA inhibition
and mimicry and varied in their statistical significance. This is not surprising, considering the mode of
action of miRNAs and thus usually mild effects of a single miRNA on the expression of a single target
gene [2,38,39]. What is more, the endogenous levels of the studied miRNAs differed in the studied
cell lines, which we considered in the interpretation of our results. Finally, the more profound effects,
which we observed in case of miRNA inhibitors than miRNA mimics, might also reflect the different
modes of action of these two types of molecules related to their different structure [40]. Despite these
imperfections of in vitro conditions, we demonstrated, either by the effects of miRNA inhibition or
miRNA mimicry, or both, that miR-20b-5p and miR-363-3p affect the levels of PTEN and BIM genes,
proteins, or both. Our immunoprecipitation results (Supplementary Figure S5) are also indicative of the
interaction of both miRNAs with PTEN and BIM in T-ALL cells in vitro and support our conclusions
from RT-qPCR and Western blotting on the regulatory roles of these miRNAs over these genes.
Interestingly, despite the existence of two potential binding sites in FBXW7 3’UTR for
hsa-miR-363-3p [41,42] we found no statistically significant evidence for this regulation in the examined
T-ALL cell lines. As for SOS1, being a putative target of hsa-miR-20b-5p, we demonstrated the
regulatory effect only in DND-41 cells (Supplementary Figure S4).
To further test our hypothesis, that hsa-miR-20b-5p and hsa-miR-363-3p act as oncogenes in T-ALL
cells in vitro, we investigated the effects of miRNA inhibition and mimicry on apoptosis, growth and
cell cycle in DND-41 and CCRF-CEM cell lines. Altogether, our results show that hsa-miR-20b-5p
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and hsa-miR-363-3p, to various extent, affect the growth of T-ALL cells by inhibiting spontaneous
apoptosis and by stimulating the proliferation, upon overexpression of these miRNAs, and by the
reverse effects (pro-apoptotic and anti-proliferative) after the inhibition of these miRNAs. Our results
point to potentially important roles of PTEN and BIM as mediators of these effects.
Of note, the functional effects of miRNAs inhibition and mimicry were more profound in
DND-41 cells than in CCRF-CEM cells. The interpretation of these observations should account for
the endogenous expression of the miRNAs of interest and their targets: DND-41 cells express both
miRNAs at high levels as compared to T-ALL primary samples and all studied controls, and express
both PTEN and BIM; CCRF-CEM cells express high level of hsa-miR-20b-5p, but relatively lower level
of hsa-miR-363-3p, and lack PTEN expression. Although the low endogenous level of hsa-miR-363-3p
might itself explain the less profound effects observed in these cells, it is also tempting to speculate that
the survival advantage of T-ALL cells is higher, when mediated by the interactions of hsa-miR-20b-5p
and hsa-miR-363-3p with both tumor suppressor genes, PTEN and BIM. Hypothetically, overexpression
of these oncogenic miRNAs might serve as an alternative oncogenic mechanism to deletions and
inactivating mutations of PTEN and contribute to loss or diminished activity of this important tumor
suppressor in T-ALL cells expressing wild type PTEN. Naturally, other genes might also be the
mediators of the impact of these miRNAs on T-ALL cells’ phenotype.
What is more, by demonstrating enhanced effects of simultaneous inhibition of hsa-miR-20b-5p
and hsa-miR-363-3p in DND-41 cells as compared to single inhibitors, we point to the cooperating
oncogenic effects of both miRNAs. The impact of simultaneous inhibition on the increasing number
of apoptotic cells, and decreasing growth rate was less evident as compared to hsa-miR-20b-5p
inhibition than as compared hsa-miR-363-3p inhibition. This might suggest the leading regulatory
role of hsa-miR-20b-5p over the cells’ growth and the cooperative role of hsa-miR-363-3p. It is
tempting to speculate, that overexpression of miRNAs from mir-106a-363 cluster might serve as an
alternative oncogenic mechanism to overexpression of miRNAs from a prototypic oncogenic cluster
mir-17-92 [43,44].
mir-106a-363 cluster is one of the two highly conserved paralogs of cluster mir-17-92; the second
paralog is mir-106b-25 [44,45]. mir-106a-363, although much less thoroughly examined than
mir-17-92, has been demonstrated to act in both oncogenic and tumor suppressor manner in various
malignancies [46–49]. Since functional effects mediated by miRNAs are highly context-dependent
(tissue-, disease-, time-specific), miRNAs having oncogenic activities in one type of cancer may act
as tumor suppressors in other malignancies. hsa-miR-20b and hsa-miR-363-5p were shown to be
downregulated and to have anti-proliferative effects in oral squamous carcinoma cells in vitro [49].
On the other hand, in an in vitro model of Ewing sarcoma, hsa-miR-20b, hsa-miR-106a, and hsa-miR-18b
were shown to be upregulated and to promote cell growth [46]. All three paralogs were proven to act
as oncogenes in several types of brain tumors, as reviewed by Gruszka et al. [47]. hsa-miR-20b-3p,
hsa-miR-20a-5p and hsa-miR-106a-5p were shown to be upregulated and negatively correlated with
PTEN expression in primary cutaneous B-cell lymphoma patients [48]. As regards the T-lymphoid
malignancies, the most extensively studied was mir-17-92 cluster, and particularly miR-19, which was
thoroughly analyzed using in vitro and in vivo T-ALL models by Mavrakis et al. [15,50]. The authors
revealed a set of tumor suppressor genes (including PTEN, BIM, and FBXW7) negatively regulated
by miRNAs from cluster mir-17-92 and suggested the potential oncogenic roles of other paralogous
clusters, yet the functional evidence for their contribution to T-ALL biology was not provided in
their study.
The potential role of mir-106a-363 cluster in T-cell malignancies has already been approached
in 2005 and 2007 by Landais et al., using murine model [51,52]. The authors showed that the locus
referred to as Kis2 (now known to be the locus of mir-106a-363 cluster) is a frequent integration site for
murine leukemia retroviruses in mouse retrovirus-induced T-cell lymphoma model. This observation
was confirmed by Lum et al., who demonstrated that this locus is frequently affected by retroviral
integration resulting in T-lymphomagenesis in mice. The authors have shown higher expression of
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murine primary mmu-mir-106a-363 transcript as well as mature mmu-miR-106a and mmu-miR-363 in
tumors with retroviral integration site within this locus as compared to tumors with other integration
sites [53]. In another study of Landais et al., they showed higher expression of mmu-miR-20b,
mmu-miR-106a, mmu-miR-19b-2 and mmu-miR-92-2 in murine retrovirus-induced T-cell lymphomas
with retroviral integration within mir-106a-363 locus as compared to lymphomas without retroviral
integration in this locus [52]. The authors additionally demonstrated overexpression of human primary
mir-106a-363 transcript in 9 human primary T-ALL samples as compared to normal mononuclear
cells from peripheral blood and suggested their oncogenic potential. Yet, lack of functional evidence
from human T-ALL cell lines or mouse models and low number of studied T-ALL patients limited the
strength of this conclusion. In 2017, Kuppers et al. demonstrated that the activation of mir-106a-363
locus together with loss of p27Kip1 (tumor suppressor involved in regulation of cell cycle) leads to
T-lymphomagenesis in murine model [54]. All these findings suggest that miRNAs encoded within
this cluster may be implicated in T-cell lymphomagenesis [51–54]. Despite these advances in the
understanding of the potential role of mir-106a-363 cluster in T-cell malignancies, no functional studies
in human T-ALL cells have been conducted so far. Thus, our results fill this research gap and provide
evidence for the potential involvement of miRNAs from mir-106a-363 cluster as oncomiRs in human
T-ALL cells.
Limitations and Future Directions
In the present study we used a transient transfection approach, which results in relatively short
duration of mimics and inhibitors in the cells and consequently time-restricted effects of miRNA
upregulation and downregulation [55]. The effects observed in the examined T-ALL cell lines, although
consistent, could be more profound with the use of stable miRNA expression approach (e.g., lentiviral
transduction system). We are also aware of the limitations of the selection of target genes for the
miRNAs of interest. Our target prediction was based on several prediction algorithms, yet only a
fraction of multiple hypotheses generated by bioinformatics approaches is usually tested in functional
experiments. Our results show that the oncogenic effects of hsa-miR-20b-5p and hsa-miR-363-3p
in T-ALL cells in vitro might be mediated by the downregulation of PTEN and BIM. Obviously,
other target genes might also contribute to the observed effects. The future direction of our research,
is the investigation of the miRNA targetome, using AGO2 RNA immunoprecipitation combined with
next generation sequencing, which allows to investigate miRNA-mediated gene regulation in a global
manner [13,56].
Our findings on the potential oncogenic roles of hsa-miR-20b-5p and hsa-miR-363-3p in T-ALL
cells can further be developed into a clinically relevant direction. This could include the integration
of miRNA-seq and mRNA-seq data from T-ALL patients’ samples to search for anti-correlation
patterns of expression of these miRNAs and PTEN, BIM, and presumably other genes implicated
in miRNA-mediated regulation of leukemic cells’ survival. In this perspective, it might also be
informative to test the effects of miRNA mimics and inhibitors in human primary T-ALL cells to
verify our observations in T-ALL cell lines. Finally, our results bring to mind the perspective of
testing the hypothetical therapeutic potential of antagonists of tumorigenic miRNAs, which might
potentially prove beneficial for T-ALL patients, when combined with standard therapy or other
therapeutic options [57–59]. Naturally, the potential benefits of such therapeutics would be limited to
a well-defined subgroup of patients (with overexpression of hsa-miR-20b-5p and hsa-miR-363-3p),
which falls into the idea of theragnostics and personalized targeted therapy in cancer [60].
5. Conclusions
Our study is the first to demonstrate anti-apoptotic and pro-proliferative effects of the
overexpression of hsa-miR-20b-5p and hsa-miR-363-3p in human T-ALL cells in vitro. We conclude
that these oncogenic effects might be mediated by the downregulation of PTEN and BIM,
two important tumor suppressor genes. We postulate that these two miRNAs from mir-106a-363 cluster,
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when overexpressed in T-ALL cells, may act as oncomiRs by affecting the regulation of apoptosis and
by favoring the proliferation, thus contributing to enhanced survival of leukemic cells.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/9/5/1137/s1,
SUMPLEMENTARY MATERIALS, Figure S1: Whole total protein membranes and chemiluminescence blots.
Figure S2: Representative apoptosis plots for DND-41 (A) and CCRF-CEM (B) cell lines after inhibition or mimicry
of hsa-miR-20b-5p and hsa-miR-363-3p. Figure S3: Validation of interaction between studied miRNAs and their
predicted target 3′UTRs in HEK293T cell line via Dual Luciferase Reporter Assay. Figure S4: Evaluation of the
expression of target genes for hsa-miR-20b-5p and hsa-miR-363-3p on mRNA and protein level after inhibition
and mimicry of these miRNAs in DND-41 and CCRF-CEM T-ALL cell lines. Figure S5: Fold enrichment of
hsa-miR-20b-5p, hsa-miR-363-3p, PTEN and BIM in AGO2-RIP fraction in reference to IgG-RIP (negative control)
fraction. Figure S6: Functional effect of simultaneous inhibition of hsa-miR-20b-5p and hsa-miR-363-3p as
compared to negative control and to inhibition of single miRNAs on cell cycle distribution in DND-41 T-ALL cell
line. Table S1: List of primers used for RT-qPCR. Table S2: List of oligonucleotides used for cloning into pmiRGLO
plasmid. Table S3: miRNA-mRNA interactions for genes overrepresented in positive regulation of apoptosis
GO term. Table S4: miRNA-3’UTR interactions of hsa-miR-20b-5p and hsa-miR-363-3p potentially involved in
positive regulation of apoptosis.
Author Contributions: Conceptualization, M.D. (Monika Drobna), B.S. and M.D. (Małgorzata Dawidowska); Data
curation, R.J.; Formal analysis, M.D. (Monika Drobna), B.S. and R.J.; Funding acquisition, M.D. (Monika Drobna),
T.S. and M.W.; Investigation, M.D. (Monika Drobna), B.S. and M.D. (Małgorzata Dawidowska); Methodology,
M.D. (Monika Drobna), B.S. and M.D. (Małgorzata Dawidowska); Project administration, M.W. and M.D.
(Małgorzata Dawidowska); Resources, Ł.S., A.K., T.T., P.V.V. and T.S.; Software, R.J.; Supervision, M.D.
(Małgorzata Dawidowska); Visualization, M.D. (Monika Drobna); Writing—original draft, M.D. (Monika Drobna)
and M.D. (Małgorzata Dawidowska); Writing—review and editing, M.D. (Monika Drobna) and M.D.
(Małgorzata Dawidowska). All authors critically revised the manuscript and approved the submitted version.
All authors have read and agreed to the published version of the manuscript.
Funding: This study was funded by the National Science Centre, Poland: 2014/15/B/NZ2/03394;
2017/25/N/NZ2/01132; National Centre of Research and Development: STRATEGMED3/304586/5/NCBR/2017;
The Fund for Scientific Research Flanders and Concerted Research Action (GOA) of the Ghent University.
Acknowledgments: The authors wish to acknowledge Maria Kosmalska (Institute of Human Genetics,
Polish Academy of Sciences) for an excellent technical assistance and contribution to the laboratory part of this work.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. De Smedt, R.; Morscio, J.; Goossens, S.; Van Vlierberghe, P. Targeting steroid resistance in T-cell acute
lymphoblastic leukemia. Blood Rev. 2019, 39, 100591. [CrossRef] [PubMed]
2. Drobna, M.; Szarzyn´ska-Zawadzka, B.; Dawidowska, M. T-cell acute lymphoblastic leukemia from miRNA
perspective: Basic concepts, experimental approaches, and potential biomarkers. Blood Rev. 2018, 32, 457–472.
[CrossRef] [PubMed]
3. Kraszewska, M.D.; Dawidowska, M.; Larmonie, N.S.D.; Kosmalska, M.; Sedek, L.; Szczepaniak, M.;
Grzeszczak, W.; Langerak, A.W.; Szczepanski, T.; Witt, M.; et al. DNA methylation pattern is altered in
childhood T-cell acute lymphoblastic leukemia patients as compared with normal thymic subsets: Insights
into CpG island methylator phenotype in T-ALL. Leukemia 2012, 26, 367–371. [CrossRef] [PubMed]
4. Kraszewska, M.D.; Dawidowska, M.; Szczepan´ski, T.; Witt, M. T-cell acute lymphoblastic leukaemia: Recent
molecular biology findings. Br. J. Haematol. 2012, 156, 303–315. [CrossRef]
5. Durinck, K.; Goossens, S.; Peirs, S.; Wallaert, A.; Van Loocke, W.; Matthijssens, F.; Pieters, T.; Milani, G.;
Lammens, T.; Rondou, P.; et al. Novel biological insights in T-cell acute lymphoblastic leukemia. Exp. Hematol.
2015, 43, 625–639. [CrossRef]
6. Belver, L.; Ferrando, A. The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat. Rev. Cancer
2016, 16, 494–507. [CrossRef]
7. Chen, B.; Jiang, L.; Zhong, M.-L.; Li, J.-F.; Li, B.-S.; Peng, L.-J.; Dai, Y.-T.; Cui, B.-W.; Yan, T.-Q.;
Zhang, W.-N.; et al. Identification of fusion genes and characterization of transcriptome features in T-cell
acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA 2018, 115, 373–378. [CrossRef]
Cells 2020, 9, 1137 17 of 19
8. Gianfelici, V.; Chiaretti, S.; Demeyer, S.; Di Giacomo, F.; Messina, M.; La Starza, R.; Peragine, N.; Paoloni, F.;
Geerdens, E.; Pierini, V.; et al. RNA sequencing unravels the genetics of refractory/relapsed T-cell acute
lymphoblastic leukemia. Prognostic and therapeutic implications. Haematologica 2016, 101, 941–950. [CrossRef]
9. Liu, Y.; Easton, J.; Shao, Y.; Maciaszek, J.; Wang, Z.; Wilkinson, M.R.; McCastlain, K.; Edmonson, M.;
Pounds, S.B.; Shi, L.; et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic
leukemia. Nat. Genet. 2017, 49, 1211–1218. [CrossRef]
10. Seki, M.; Kimura, S.; Isobe, T.; Yoshida, K.; Ueno, H.; Nakajima-Takagi, Y.; Wang, C.; Lin, L.; Kon, A.;
Suzuki, H.; et al. Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia.
Nat. Genet. 2017, 49, 1274–1281. [CrossRef]
11. Wallaert, A.; Van Loocke, W.; Hernandez, L.; Taghon, T.; Speleman, F.; Van Vlierberghe, P. Comprehensive
miRNA expression profiling in human T-cell acute lymphoblastic leukemia by small RNA-sequencing.
Sci. Rep. 2017, 7, 7901. [CrossRef] [PubMed]
12. Dawidowska, M.; Jaksik, R.; Drobna, M.; Szarzyn´ska-Zawadzka, B.; Kosmalska, M.; Se˛dek, Ł.; Machowska, L.;
Lalik, A.; Lejman, M.; Ussowicz, M.; et al. Comprehensive Investigation of miRNome Identifies Novel
Candidate miRNA-mRNA Interactions Implicated in T-Cell Acute Lymphoblastic Leukemia. Neoplasia 2019,
21, 294–310. [CrossRef] [PubMed]
13. Dzikiewicz-Krawczyk, A.; Kok, K.; Slezak-Prochazka, I.; Robertus, J.L.; Bruining, J. ZDHHC11 and
ZDHHC11B are critical novel components of the oncogenic MYC-miR-150-MYB network in Burkitt lymphoma.
Leukemia 2017, 31, 1470–1473. [CrossRef]
14. Zhang, X.; Wang, S.; Wang, H.; Cao, J.; Huang, X.; Chen, Z.; Xu, P.; Sun, G.; Xu, J.; Lv, J.; et al. Circular RNA
circNRIP1 acts as a microRNA-149-5p sponge to promote gastric cancer progression via the AKT1/mTOR
pathway. Mol. Cancer 2019, 18, 20. [CrossRef] [PubMed]
15. Mavrakis, K.J.; Wolfe, A.L.; Oricchio, E.; Palomero, T.; de Keersmaecker, K.; McJunkin, K.; Zuber, J.; James, T.;
Chang, K.; Khan, A.A.; et al. Genome-wide RNA-mediated interference screen identifies miR-19 targets in
Notch-induced T-cell acute lymphoblastic leukaemia. Nat. Cell Biol. 2010, 12, 372–379. [CrossRef]
16. Drobna, M.; Szarzyn´ska-Zawadzka, B.; Daca-Roszak, P.; Kosmalska, M.; Jaksik, R.; Witt, M.; Dawidowska, M.
Identification of Endogenous Control miRNAs for RT-qPCR in T-Cell Acute Lymphoblastic Leukemia. Int. J.
Mol. Sci. 2018, 19. [CrossRef]
17. Taghon, T.; Waegemans, E.; Van de Walle, I. Notch signaling during human T cell development. Curr. Top.
Microbiol. Immunol. 2012, 360, 75–97.
18. Schmittgen, T.D.; Livak, K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc.
2008, 3, 1101–1108. [CrossRef]
19. Squiban, B.; Ahmed, S.T.; Frazer, J.K. Creation of a human T-ALL cell line online database. Leuk. Lymphoma
2017, 58, 2728–2730. [CrossRef]
20. Palomero, T.; Sulis, M.L.; Cortina, M.; Real, P.J.; Barnes, K.; Ciofani, M.; Caparros, E.; Buteau, J.; Brown, K.;
Perkins, S.L.; et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia.
Nat. Med. 2007, 13, 1203–1210. [CrossRef]
21. Shukla, S.; Saxena, S.; Singh, B.K.; Kakkar, P. BH3-only protein BIM: An emerging target in chemotherapy.
Eur. J. Cell Biol. 2017, 96, 728–738. [CrossRef] [PubMed]
22. Palomero, T.; Dominguez, M.; Ferrando, A.A. The role of the PTEN/AKT Pathway in NOTCH1-induced
leukemia. Cell Cycle Georget. Tex 2008, 7, 965–970. [CrossRef] [PubMed]
23. Jing, D.H.; Bhadri, V.A.; Beck, D.; Thoms, J.A.I.; Yakob, N.A.; Wong, J.W.H.; Knezevic, K.; Pimanda, J.E.;
Lock, R.B. Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric
acute lymphoblastic leukemia cells. Blood 2015, 125, 273–283. [CrossRef] [PubMed]
24. Bader, A.G.; Kang, S.; Zhao, L.; Vogt, P.K. Oncogenic PI3K deregulates transcription and translation.
Nat. Rev. Cancer 2005, 5, 921–929. [CrossRef]
25. Samuels, Y.; Ericson, K. Oncogenic PI3K and its role in cancer. Curr. Opin. Oncol. 2006, 18, 77–82. [CrossRef]
26. Szarzyn´ska-Zawadzka, B.; Kunz, J.B.; Se˛dek, Ł.; Kosmalska, M.; Zdon, K.; Biecek, P.; Bandapalli, O.R.;
Kraszewska-Hamilton, M.; Jaksik, R.; Drobna, M.; et al. PTEN abnormalities predict poor outcome in children
with T-cell acute lymphoblastic leukemia treated according to ALL IC-BFM protocols. Am. J. Hematol. 2019,
94, E93–E96. [CrossRef]
Cells 2020, 9, 1137 18 of 19
27. Tesio, M.; Trinquand, A.; Ballerini, P.; Hypolite, G.; Lhermitte, L.; Petit, A.; Ifrah, N.; Baruchel, A.;
Dombret, H.; Macintyre, E.; et al. Age-related clinical and biological features of PTEN abnormalities in T-cell
acute lymphoblastic leukaemia. Leukemia 2017, 31, 2594–2600. [CrossRef]
28. Bandapalli, O.R.; Zimmermann, M.; Kox, C.; Stanulla, M.; Schrappe, M.; Ludwig, W.-D.; Koehler, R.;
Muckenthaler, M.U.; Kulozik, A.E. NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN
inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia. Haematologica 2013,
98, 928–936. [CrossRef]
29. Paganin, M.; Grillo, M.F.; Silvestri, D.; Scapinello, G.; Buldini, B.; Cazzaniga, G.; Biondi, A.; Valsecchi, M.G.;
Conter, V.; Te Kronnie, G.; et al. The presence of mutated and deleted PTEN is associated with an increased
risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with AIEOP-BFM ALL protocols.
Br. J. Haematol. 2018, 182, 705–711. [CrossRef]
30. Reynolds, C.; Roderick, J.E.; LaBelle, J.L.; Bird, G.; Mathieu, R.; Bodaar, K.; Colon, D.; Pyati, U.; Stevenson, K.E.;
Qi, J.; et al. Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute
lymphoblastic leukemia. Leukemia 2014, 28, 1819–1827. [CrossRef]
31. Hall, C.P.; Reynolds, C.P.; Kang, M.H. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute
Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235. Clin. Cancer
Res. Off. J. Am. Assoc. Cancer Res. 2016, 22, 621–632.
32. King, B.; Trimarchi, T.; Reavie, L.; Xu, L.; Mullenders, J.; Ntziachristos, P.; Aranda-Orgilles, B.; Perez-Garcia, A.;
Shi, J.; Vakoc, C.; et al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating
MYC stability. Cell 2013, 153, 1552–1566. [CrossRef] [PubMed]
33. Schaub, F.X.; Dhankani, V.; Berger, A.C.; Trivedi, M.; Richardson, A.B.; Shaw, R.; Zhao, W.; Zhang, X.;
Ventura, A.; Liu, Y.; et al. Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the
Cancer Genome Atlas. Cell Syst. 2018, 6, 282–300.e2. [CrossRef] [PubMed]
34. Radtke, F.; Wilson, A.; Stark, G.; Bauer, M.; van Meerwijk, J.; MacDonald, H.R.; Aguet, M. Deficient T cell fate
specification in mice with an induced inactivation of Notch1. Immunity 1999, 10, 547–558. [CrossRef]
35. Ebinu, J.O.; Stang, S.L.; Teixeira, C.; Bottorff, D.A.; Hooton, J.; Blumberg, P.M.; Barry, M.; Bleakley, R.C.;
Ostergaard, H.L.; Stone, J.C. RasGRP links T-cell receptor signaling to Ras. Blood 2000, 95, 3199–3203.
[CrossRef]
36. Pierre, S.; Bats, A.-S.; Coumoul, X. Understanding SOS (Son of Sevenless). Biochem. Pharmacol. 2011, 82,
1049–1056. [CrossRef]
37. Kortum, R.L.; Sommers, C.L.; Alexander, C.P.; Pinski, J.M.; Li, W.; Grinberg, A.; Lee, J.; Love, P.E.;
Samelson, L.E. Targeted Sos1 deletion reveals its critical role in early T-cell development. Proc. Natl. Acad.
Sci. USA 2011, 108, 12407–12412. [CrossRef]
38. Bartel, D.P. MicroRNAs: Target Recognition and Regulatory Functions. Cell 2009, 136, 215–233. [CrossRef]
39. Bracken, C.P.; Scott, H.S.; Goodall, G.J. A network-biology perspective of microRNA function and dysfunction
in cancer. Nat. Rev. Genet. 2016, 17, 719–732. [CrossRef]
40. Thomson, D.W.; Bracken, C.P.; Szubert, J.M.; Goodall, G.J. On Measuring miRNAs after Transient Transfection
of Mimics or Antisense Inhibitors. PLoS ONE 2013, 8, e55214. [CrossRef]
41. Zhang, P.-F.; Sheng, L.-L.; Wang, G.; Tian, M.; Zhu, L.-Y.; Zhang, R.; Zhang, J.; Zhu, J.-S. miR-363 promotes
proliferation and chemo-resistance of human gastric cancer via targeting of FBW7 ubiquitin ligase expression.
Oncotarget 2016, 7, 35284–35292. [CrossRef] [PubMed]
42. Peer, G.V.; Mets, E.; Claeys, S.; Punt, I.D.; Lefever, S.; Ongenaert, M.; Rondou, P.; Speleman, F.; Mestdagh, P.;
Vandesompele, J. A high-throughput 3’ UTR reporter screening identifies microRNA interactomes of cancer
genes. PLoS ONE 2018, 13, e0194017.
43. Olive, V.; Jiang, I.; He, L. mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int. J. Biochem.
Cell Biol. 2010, 42, 1348–1354. [CrossRef] [PubMed]
44. Khuu, C.; Utheim, T.P.; Sehic, A. The Three Paralogous MicroRNA Clusters in Development and Disease,
miR-17-92, miR-106a-363, and miR-106b-25. Scientifica (Cairo) 2016, 2016, 1379643. [CrossRef]
45. Tanzer, A.; Stadler, P.F. Molecular evolution of a microRNA cluster. J. Mol. Biol. 2004, 339, 327–335. [CrossRef]
46. Dylla, L.; Jedlicka, P. Growth-Promoting Role of the miR-106a∼363 Cluster in Ewing Sarcoma. PLoS ONE
2013, 8, e63032. [CrossRef]
47. Gruszka, R.; Zakrzewska, M. The Oncogenic Relevance of miR-17-92 Cluster and Its Paralogous miR-106b-25
and miR-106a-363 Clusters in Brain Tumors. Int. J. Mol. Sci. 2018, 19, 879. [CrossRef]
Cells 2020, 9, 1137 19 of 19
48. Battistella, M.; Romero, M.; Castro-Vega, L.-J.; Gapihan, G.; Bouhidel, F.; Bagot, M.; Feugeas, J.-P.; Janin, A.
The High Expression of the microRNA 17-92 Cluster and its Paralogs, and the Downregulation of the Target
Gene PTEN, Is Associated with Primary Cutaneous B-Cell Lymphoma Progression. J. Investig. Dermatol.
2015, 135, 1659–1667. [CrossRef]
49. Khuu, C.; Jevnaker, A.-M.; Bryne, M.; Osmundsen, H. An investigation into anti-proliferative effects of
microRNAs encoded by the miR-106a-363 cluster on human carcinoma cells and keratinocytes using
microarray profiling of miRNA transcriptomes. Front. Genet. 2014, 5. [CrossRef]
50. Mavrakis, K.J.; Van der Meulen, J.; Wolfe, A.L.; Liu, X.P.; Mets, E.; Taghon, T.; Khan, A.A.; Setti, M.;
Rondou, P.; Vandenberghe, P.; et al. A cooperative microRNA-tumor suppressor gene network in acute T-cell
lymphoblastic leukemia (T-ALL). Nat. Genet. 2011, 43, 673. [CrossRef]
51. Landais, S.; Quantin, R.; Rassart, E. Radiation Leukemia Virus Common Integration at the Kis2 Locus:
Simultaneous Overexpression of a Novel Noncoding RNA and of the Proximal Phf6 Gene. J. Virol. 2005, 79,
11443–11456. [CrossRef] [PubMed]
52. Landais, S.; Landry, S.; Legault, P.; Rassart, E. Oncogenic potential of the miR-106-363 cluster and its
implication in human T-cell leukemia. Cancer Res. 2007, 67, 5699–5707. [CrossRef] [PubMed]
53. Lum, A.M.; Wang, B.B.; Li, L.; Channa, N.; Bartha, G.; Wabl, M. Retroviral activation of the mir-106a
microRNA cistron in T lymphoma. Retrovirology 2007, 4, 5. [CrossRef] [PubMed]
54. Kuppers, D.A.; Schmitt, T.M.; Hwang, H.C.; Samraj, L.; Clurman, B.E.; Fero, M.L. The miR-106a~363Xpcl1
miRNA cluster induces murine T cell lymphoma despite transcriptional activation of the p27Kip1 cell cycle
inhibitor. Oncotarget 2017, 8, 50680–50691. [CrossRef]
55. Jin, H.Y.; Gonzalez-Martin, A.; Miletic, A.V.; Lai, M.; Knight, S.; Sabouri-Ghomi, M.; Head, S.R.; Macauley, M.S.;
Rickert, R.C.; Xiao, C. Transfection of microRNA Mimics Should Be Used with Caution. Front. Genet. 2015, 6.
[CrossRef]
56. Ottaviani, S.; Stebbing, J.; Frampton, A.E.; Zagorac, S.; Krell, J.; de Giorgio, A.; Trabulo, S.M.; Nguyen, V.T.M.;
Magnani, L.; Feng, H.; et al. TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B
controlling PDAC progression. Nat. Commun. 2018, 9, 1845. [CrossRef]
57. Reid, G.; Johnson, T.G.; van Zandwijk, N. Manipulating microRNAs for the Treatment of Malignant Pleural
Mesothelioma: Past, Present and Future. Front. Oncol. 2020, 10, 105. [CrossRef]
58. Caracciolo, D.; Montesano, M.; Altomare, E.; Scionti, F.; Di Martino, M.T.; Tagliaferri, P.; Tassone, P. The
potential role of miRNAs in multiple myeloma therapy. Expert Rev. Hematol. 2018, 11, 793–803. [CrossRef]
59. Takahashi, R.-U.; Prieto-Vila, M.; Kohama, I.; Ochiya, T. Development of miRNA-based therapeutic
approaches for cancer patients. Cancer Sci. 2019, 110, 1140–1147. [CrossRef]
60. Pepe, F.; Balatti, V. Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy
Approaches for Chronic Lymphocytic Leukemia. J. Clin. Med. 2020, 9. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
